ecteinascidin 743 has been researched along with Invasiveness, Neoplasm in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hirabayashi, K; Kikuta, K; Kondo, T; Noguchi, R; Ono, T; Ozawa, I; Sei, A; Yoshimatsu, Y | 1 |
| Bernard, A; Dirix, L; Herremans, C; Keung, C; Khokhar, NZ; Knoblauch, R; Machiels, JP; Parekh, TV; Phelps, C; Sharma, S; Staddon, A | 1 |
| Barton, S; Edwards, SJ; Thurgar, E; Trevor, N | 1 |
| Dumez, H; Jimeno, J; Schöffski, P; Stefan, C; Van Oosterom, AT; Wolter, P; Wozniak, A | 1 |
| Alberti, L; Blay, JY; Boyle, H; Cassier, P; Chabaud, S; Decouvelaere, AV; Engel, C; Favier, B; Fayette, J; Méeus, P; Pérol, D; Ranchère, D; Ray-Coquard, I; Sunyach, MP; Thiesse, P; Vaz, G | 1 |
| Allavena, P; Mantovani, A | 1 |
3 review(s) available for ecteinascidin 743 and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom | 2015 |
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Disease-Free Survival; Humans; Molecular Structure; Neoplasm Invasiveness; Neoplasm Metastasis; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2008 |
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; Clodronic Acid; Cytokines; Dioxoles; Disease Progression; Humans; Immunity, Innate; Inflammation; Liposomes; Macrophages; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Tetrahydroisoquinolines; Trabectedin; Tumor Escape; Tumor Microenvironment | 2012 |
2 trial(s) available for ecteinascidin 743 and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Monitoring; Drug Screening Assays, Antitumor; Drug-Related Side Effects and Adverse Reactions; Enzyme Activators; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Rifampin; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Compassionate Use Trials; Dioxoles; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Proportional Hazards Models; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2010 |
1 other study(ies) available for ecteinascidin 743 and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 12; Depsipeptides; Female; Gene Dosage; Humans; Karyotype; Liposarcoma; Neoplasm Invasiveness; Spheroids, Cellular; Trabectedin | 2021 |